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Abstract
Background: Probiotics are increasingly applied to prevent and treat a range of infectious, immune related and
gastrointestinal diseases. Despite this, the mechanisms behind the putative effects of probiotics are poorly
understood. One of the suggested modes of probiotic action is modulation of the endogenous gut microbiota, however
probiotic intervention studies in adults have failed to show significant effects on gut microbiota composition. The gut
microbiota of young children is known to be unstable and more responsive to external factors than that of
adults. Therefore, potential effects of probiotic intervention on gut microbiota may be easier detectable in early
life. We thus investigated the effects of a 6 month placebo-controlled probiotic intervention with Bifidobacterium animalis
subsp. lactis (BB-12®) and Lactobacillus rhamnosus (LGG®) on gut microbiota composition and diversity in more than 200
Danish infants (N = 290 enrolled; N = 201 all samples analyzed), as assessed by 16S rRNA amplicon sequencing. Further,
we evaluated probiotic presence and proliferation by use of specific quantitative polymerase chain reaction (qPCR).
Results: Probiotic administration did not significantly alter gut microbiota community structure or diversity as compared
to placebo. The probiotic strains were detected in 91.3% of the fecal samples from children receiving probiotics and in
1% of the placebo treated children. Baseline gut microbiota was not found to predict the ability of probiotics to establish
in the gut after the 6 month intervention. Within the probiotics group, proliferation of the strains LGG® and BB-12® in the
gut was detected in 44.7% and 83.5% of the participants, respectively. A sub-analysis of the gut microbiota
including only individuals with detected growth of the probiotics LGG® or BB-12® and comparing these to
placebo revealed no differences in community structure or diversity.
Conclusion: Six months of probiotic administration during early life did not change gut microbiota community structure
or diversity, despite active proliferation of the administered probiotic strains. Therefore, alteration of the healthy infant gut
microbiota is not likely to be a prominent mechanism by which these specific probiotics works to exert beneficial effects
on host health.
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Background
Probiotics are defined as “live microorganisms which,
when administered in adequate amounts, confer a health
benefit on the host” [1]. Several mechanisms behind pro-
biotic effects have been suggested, including modulation
of the endogenous gut microbiota [2–4]. However, a
recent meta-analysis of seven probiotic intervention
studies showed that probiotic administration did not
affect the adult gut microbiota as determined by analysis
of fecal samples [5]. Still, in infants and children, the
microbiota is known to be much more variable [6] and
easier to manipulate [7] than seen for adults. Thus, if
alteration of the gut microbiota composition is a mechan-
ism by which probiotics exert their beneficial effect, this
would be expected to be evident in early life interventions.
In the present study, we have analyzed the fecal micro-
biota of healthy infants at the age of starting daycare (age
8–13 months), sampled before and after a 6 months
intervention with a single daily dose of Lactobacillus
rhamnosus (LGG®) and Bifidobacterium animalis subsp.
lactis (BB-12®) or placebo. Additionally, in contrast to
previous studies, we specifically assessed the presence
and proliferation of the probiotic strains in the gut, and
evaluated the effect on the endogenous microbial com-
position and diversity based on probiotic propagation.
Methods
Study participants
Infants, aged 8–14 months and starting daycare within
12 weeks after intervention start, were included in the
ProbiComp study [8], a double blinded randomized
placebo-controlled intervention. BB-12® and LGG® are
registered trademarks of Chr. Hansen A/S who kindly
provided the study products. During the 6 months inter-
vention period participants were randomized to receive
either a combination of the two probiotics BB-12® and
LGG® at a dose of 109 colony-forming units (CFU) each,
or a placebo (maltodextrin), during the winter season.
Participants were instructed not to consume food prod-
ucts and supplements containing probiotics 2 weeks
prior to and during the intervention period. The study
spanned two consecutive winter seasons and included a
total of 290 infants (145 for each season). Study popula-
tion characteristics (Table 1) were obtained through par-
ental interviews.
Table 1 Characteristics of study participants with gut microbiota data completing the study (n = 201)
Parameter Probiotics group
(n = 103)
Placebo group
(n = 98)
P-value
Gender
Girls (%) 45.6 46.9 0.888a
Boys (%) 54.4 53.1
Mode of delivery
C-section (%) 23.3 15.3 0.159a
Vaginal (%) 76.7 84.7
Older siblings
Siblings (%) 48.5 43.9 0.572a
No siblings (%) 51.5 56.1
Introduction of selected foods
Cow’s milk (median months, IQR) 8.0 (7.0–12.0) 9.0 (6.0–11.0) 0.947b
Meat (median months, IQR) 6.0 (6.0–7.0) 6.0 (6.0–7.0) 0.242b
Fish (median months, IQR) 6.0 (6.0–7.0) 6.0 (6.0–7.0) 0.544b
Breastfeeding prevalence
1st visit (%) 54.4 46.9 0.325a
2nd visit (%) 13.6 9.2 0.380a
Age
1st visit (median months, IQR) 10.0 (9.5–10.4) 9.8 (9.5–10.4) 0.462b
Start daycare (median months, IQR) 10.4 (9.9–11.2) 10.3 (9.9–11.1) 0.309b
2nd visit (median months, IQR) 16.1 (15.6–16.5) 16.0 (15.6–16.4) 0.510b
Compliance
2nd visit (median % of consumed sticks, IQR) 97 (93–99) 98 (94–100) 0.417b
aFishers exact test
bMann Whitney test
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Fecal samples, DNA extraction and PCR amplification of
theV3 region of the 16S rRNA gene
Fecal samples obtained before (N = 265, age 8–13 months)
and after (N = 210, age 14–19 months) the intervention
were freshly delivered on the morning of the visit or had
been stored in the participant’s home, either in the freezer
(−18 °C) or in the fridge (4 °C) for maximally 24 h before
delivery to the University of Copenhagen, Department of
Nutrition, Exercise and Sports, where they were stored
at −80 °C until DNA extraction. Extraction was done in
random order, but the two samples obtained from the
same child were always processed together (N = 16–20
samples/extraction round). 250 mg feces was applied
and treated according to the protocol provided by the
manufacturer (PowerLyzer® PowerSoil® DNA isolation
kit, MoBio 12,855–100) with minor modifications: Bead
beating was performed at 30 cycles/s for 10 min (Retsch
MM 300 mixer mill) and the initial centrifugation steps were
performed at 10,000 x g for 3 min, as recommended for clay
matter. DNA quantity and quality was measured by Nano-
Drop® 1000 (ThermoFisher Scientific), yielding on average
85.0 ± 47.1 ng/μl DNA with A260/A280 = 1.89 ± 0.10 and
A260/A230 = 1.71 ± 0.39. The PCR amplification of the V3-
region of the 16S rRNA gene was performed with 5 ng com-
munity DNA as template, using 0.2 μl Phusion High-Fidelity
DNA polymerase (Fisher Scientific, F-553 L), 4 μl HF-buffer,
0.4 μl dNTP (10 mM of each base), 1 μM forward primer
(PBU 5′-A-adapter-TCAG-barcode-CCTACGGGAGGCA
GCAG-3′) and 1 μM reverse primer (PBR 5′-trP1-adapter-
ATTACCGCGGCTGCTGG-3′) in 20 μl total reaction
volume. Both primers included sequencing adaptors
and the forward primer additionally a unique 10–12 bp
barcode (Ion Xpress™ Barcode Adapters). PCR amplifi-
cation included 30s at 98 °C, 24 cycles of 15 s at 98 °C
and 30s at 72 °C, followed by 5 min at 72 °C. PCR prod-
ucts were purified by use of HighPrep™ PCR Magnetic
Beads (MAGBIO®, AC-60005) with the 96-well magnet
stand (MAGBIO®, MyMag 96), according to the manufac-
turers recommendations. DNA quantity was measured
using Qubit® dsDNA HS assay (Invitrogen™, Q32851) and
a total of 456 samples contained sufficient DNA for se-
quencing. Samples were pooled to obtain equimolar li-
braries containing up to 86 samples (randomized across
treatment groups and age) in each library.
DNA sequencing and data handling
Sequencing of the 16S rRNA amplicon libraries was
performed using the Ion OneTouch™ and Ion PGM
platform with a 318-Chip v2, generating 4–5 million
reads per chip with a median length of 180 bp. Sequencing
data were imported into CLC Genomic Workbench
(version 8.5. CLC bio, Qiagen, Aarhus, DK) and using
the NGS core tools, reads were assessed for quality (QC re-
port), de-multiplexed according to barcode (Demultiplexing)
and trimmed (Trim sequences) to remove barcodes and
PCR primers (minimum alignment score 17/17, discard
when both primers were not found) and to discard
reads below 125 bp and above 180 bp. Quality filtering
(−fastq_filter, maxee 1.0), dereplication (−derep_fulllength),
OTU clustering (−cluster_otus, minsize 4), chimera filtering
(−uchime_ref, RDP_gold database), mapping of reads to
OTUs (−usearch_global, id 97%) and generation of OTU
table (python, uc2otutab.py) was done according to
the UPARSE pipeline [9], generating a total of 1096
non-chimeric OTUs (Operational Taxonomic Units).
In QIIME [10], the OTU table was filtered (filter_otus_-
from_otu_table.py/filter_fasta.py) to exclude OTUs with
average relative abundance below 0.005% of the total com-
munity, resulting in 330 OTUs. Taxonomy was assigned
(assign_taxonomy.py), using the rdp classifier with confi-
dence threshold 0.5 (recommended for sequences shorter
than 250 bp [11]) and the GreenGenes database v. 13.8
[12]. In addition, the taxonomy of selected OTUs was
confirmed/disconfirmed by BLAST [13] search against the
16S rRNA sequence database. Based on PyNAST align-
ment of representative OTU sequences (align_seqs.py, fil-
ter_alignment.py, default settings), including an archaea
(Methanosarcina) full length 16S rRNA gene sequence as
outgroup for rooting, a phylogenetic tree was created with
FastTree (make_phylogeny.py, default settings) and re-
rooted to the outgroup, which was subsequently pruned,
using Dendroscope v3.5.7 [14]. Taxon abundances (average
classification: Phylum: 100%, Family: 99.9%, Genus: 91.8%)
and alpha diversity (Shannon index, Observed OTUs,
Pielou’s evenness index) and beta diversity (UniFrac
distances) were calculated in QIIME (summarize_taxa.py,
alpha_rarefaction.py, beta_diversity_through_plots.py), with
the sequencing depth rarefied to 10,000 sequences per sam-
ple for diversity analysis. OTU abundances were estimated
by total sum scaling.
Detection of the probiotic strains BB-12® and LGG®
Primer design, PCR and gel electrophoresis
Primers specific for the probiotic strains were designed
using the primer3 online software tool (http://bioinfo.ut.ee/
primer3-0.4.0/). Selection of primers for the LGG® strain
were based on a phage-related gene target sequence [15]
previously reported to be strain specific [16], whereas
primers for the BB-12® strain were selected within the
CRISPR-Cas system [17], specifically the Type I-U CRISPR-
Cas7 gene in BB-12® (for primer sequences see Additional
file 1: Table S1). Each PCR reaction contained 14.92 μl
DNAse-free water, 2 μl 10X Accuprime PCR buffer II, 1 μl
forward primer (0.5 μM final conc.), 1 μl reverse primer
(final conc. 0.5 μM), 0.08 μl AccuPrime Taq Polymerase
(Invitrogen, 12,346–086) and 1 μl template DNA (1 ng/ul)
in a final volume of 20 ul. The PCR program (Veriti
Thermal Cycler, Applied Biosystems™, 4,452,300) included
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2 min at 94 °C, 35 cycles of 20 s at 94 °C, 20 s at 65 °C
and 30 s at 68 °C, followed by a final extension for 5 min
at 68 °C. The PCR products were separated on a 1.5%
agarose gel with 1:10,000 volume SYBR safe (Bio-Rad) for
1 h at 100 V before imaging (Molecular Imager® GelDoc™
XR System).
Primer validation and probiotic quantification
To validate primer specificity, a selection of Lactobacillus
and Bifidobacterium strains were cultivated on MRS (de
Man, Rogosa and Sharpe, [18]) or BSM (Sigma, 88,517)
agar at 37 °C under anaerobic conditions for 72 h
(Additional file 1: Table S2). Genomic DNA was extracted
(PowerLyzer® PowerSoil® DNA isolation kit, MoBio 12,855–
100) from colony material according to the protocol pro-
vided by the manufacturer and diluted to 1 ng/μl and used
for input in the PCR. For spiking fecal samples with known
quantities of the strains LGG® and BB-12®, single colonies
of these were propagated in 10 ml MRS medium under
anaerobic conditions for 48 h at 37 °C, centrifuged at
10,000×g for 5 min at 4 °C, re-suspended in 1 ml maximum
recovery diluent (MRD, Oxoid CM0733), and 10-fold
serially diluted in MRD. One hundred μl of each dilu-
tion (100–10−7) was spiked into 100 mg LGG®/BB-12®
negative baseline fecal samples (based on specific qPCR
of the probiotic strains) and also plated in duplicates
(dilutions 10−4–10−9) on MRS plates and incubated
anaerobically at 37 °C for 24 h before CFU counting.
Community DNA was extracted (PowerLyzer® PowerSoil®
DNA isolation kit, MoBio 12,855–100) from each spiked
samples plus none-spiked controls.
Quantitative PCR
Each quantitative PCR (qPCR) reaction contained 5 μl
PCR-grade water, 1 μl forward primer (final conc. 0.5 μM),
1 μl reverse primer (final conc. 0.5 μM), 10 μl SYBR Green
I Master 2X (LightCycler® 480 SYBR Green I Master,
Roche, 04887352001) and 2 μl template DNA, in a 20 μl
total volume. Template DNA was either 10-fold serial dilu-
tions of 1 ng/μl DNA extracted from pure cultures of LGG®
or BB-12®, community DNA isolated from fecal samples
(LGG®/BB-12® negative) spiked with 10-fold serial dilutions
of LGG® or BB-12® cultures, or community DNA (5 ng/μl)
extracted from fecal samples obtained during the interven-
tion. Triplicate samples were run on the qPCR instrument
(LightCycler® 480 Instrument II, Roche, 05015243001) and
the program included 5 min pre-incubation at 95 °C,
followed by 45 cycles with 10 s at 95 °C, 15 s at 65 °C and
15 s at 72 °C. A melting curve analysis was subsequently
performed with 5 min at 95 °C, 1 min at 65 °C and continu-
ous temperature increase (ramp rate 0.11 °C/s) until 98 °C.
Data were analyzed with the LightCycler® 480 Software
(v 1.5) and levels of the strains LGG® and BB-12® in
samples were quantified based on standard curves generated
from extracted community DNA of fecal samples spiked
with 10-fold serial diluted DNA extracted from pure cul-
tures of LGG® or BB-12®. Samples were regarded LGG® and/
or BB-12® positive when at least 2 of the 3 replicates were
positive, the melting curves were consistent with that of
pure cultures of the respective strains, and Ct values were
within the detection range achieved for the 10-fold dilution
series standard-curves.
Statistics
Statistics were performed with the GraphPad Prism
software (v. 7.0, GraphPad Software Inc., La Jolla, CA),
using the Spearman’s rank correlation, Mann-Whitney
test and Fisher’s exact test or by use of specific scripts
for analyzing sequencing data as implemented in QIIME v.
1.9 [10]. For comparison of beta diversity the compare_cate-
gories.py (adonis, permutations = 999) script was used and
for comparison of microbial composition at different taxo-
nomical levels the group_significance.py (mann_whitney_u,
Benjamini-Hochberg False Discovery Rate (FDR) correction
[19], threshold 0.05) script was applied. Alpha diversity
measures were compared between groups using the
Mann-Whitney test of the average of 10 iterated values
obtained following rarefying to 10,000 reads per sample.
Results
Study population characteristics and compliance
There were no statistically significant differences in gender,
mode of delivery, age at introduction to selected foods
(cow’s milk, fish and meat), breastfeeding prevalence,
presence of older siblings, age at daycare start or age at
samplings between the probiotics and the placebo groups,
thus these parameters are unlikely to have affected our re-
sults (Table 1). Median compliance to the assigned treat-
ments was 97% and 98% in the probiotics and placebo
groups, respectively (Table 1).
Microbiota profiling
Sequencing of the V3 region of the 16S rRNA genes was
successful for a total of 456 fecal samples collected
before (n = 255) and after (n = 201) intervention, and re-
sulted in 11.8 million trimmed and quality filtered reads.
A significant shift in alpha diversity (Shannon index,
p < 0.0001, Mann Whitney) and beta diversity (Weighted
UniFrac, R2 = 0.061, p = 0.001, Adonis) was observed dur-
ing the 6 months intervention period (Additional file 1:
Figure S1), which confirm a strong impact of age on gut
microbiota in agreement with previous reports [20, 21].
At baseline, no differences in beta diversity (Weighted
UniFrac, R2 = 0.010, p = 0.226, Adonis), or alpha diversity
(Shannon index, p = 0.868, Pielou’s evenness index,
p = 0.562 and Observed OTUs, p = 0.821) were observed
between the treatment group and the placebo group
(Additional file 1: Figure S2). Further, no OTUs were
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significantly differently abundant between the two groups
after FDR correction (Additional file 1: Table S3). After
the intervention, Principle Coordinate Analysis (PCoA) of
both weighted and unweighted UniFrac distances did not
result in visible separation of samples according to treat-
ment group (Fig. 1a), although Adonis testing revealed a
significant difference between the unweighted distances
caused by the specific presence of the probiotics as de-
scribed in the next section. Estimates of alpha diversity
did not differ between treatment groups (Fig. 1b). Only
two OTUs were found to be significantly differently abun-
dant following FDR correction (Table 2). These were
designated OTU_17 and OTU_50, and were assigned to
Bifidobacterium pseudolongum and Lactobacillus zeae
respectively by the GreenGenes classifier. However, a
BLAST search against the 16S rRNA gene database re-
vealed that they had 100% homology to the V3 regions
of the two probiotic strains included in the interven-
tion, namely B. animalis subsp. lactis and L. rhamnosus
strains, respectively (Table 2). Testing for differential
abundances at family and genus levels revealed only
Lactobacillaceae/Lactobacillus as significantly higher
in the probiotics group than in the placebo group
(FDR adjusted p-valuefamily = 3.9 × 10
−14; FDR adjusted
p-valuegenus = 9.1 × 10
−14), reflecting the increased
abundance of the LGG® strain in the probiotics group
Fig. 1 Administration of probiotics does not alter diversity and composition of the infant gut microbiota. a PCoA plots of weighted and unweighted
UniFrac distances of the gut microbiota, b boxplots of gut microbial alpha diversity measures, and c boxplots of relative abundance of gut microbial
families after probiotic (orange) or placebo (blue) intervention
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(Fig. 1c). Exclusion of subjects known to have consumed
infant formula containing any type of probiotics at any
given point during the intervention yielded similar results.
Quantification of probiotic strains in fecal samples
Design of primers specifically targeting the probiotics
LGG® and BB-12® (Additional file 1: Figure S3) allowed
qPCR based quantification of these strains in the samples
obtained after intervention. Strong correlations between
qPCR-estimated abundances of the strain LGG® and rela-
tive abundance of OTU_50 (rho = 0.79, p < 0.0001) as well
as between qPCR-estimated abundances of the strain BB-
12® and relative abundance of OTU_17 (rho = 0.89,
p < 0.0001), confirmed that the two OTUs represented the
two probiotic strains. When these two OTUs were omit-
ted, an unweighted UniFrac analysis with Adonis test no
longer indicated any difference between the probiotic and
the placebo group (R2 = 0.004, p = 0.670). By specific
qPCR, both of the probiotic strains were detected in
91.3% of the infants that received probiotics and only in
1.0% of the infants receiving placebo (Table 3). The strain
LGG® was detected in 91.3% whereas the strain BB-12®
was detected in 95.1% of the infants treated with pro-
biotics. However, while the LGG® strain specific primers
produced an amplicon in only 2.0% of the individuals
receiving placebo, the BB-12® strain primers, which are
subspecies-specific, but not strain-specific (Additional file 1:
Figure S3), amplified a target in 31.1% of the placebo treated
infants (Table 3), suggesting an endogenous occurrence of
B. animalis subsp. lactis as found in previous studies [22],
or eventual prior ingestion of infant formula containing
related strains. The qPCR-estimated abundances of the
strain BB-12® (range 1.3 × 104 to 1.5 × 1010 CFU/g feces)
and the strain LGG® (1.5 × 104 to 1.4 × 109 CFU/g feces)
showed high inter-individual variation. Since this vari-
ation may reflect differences in colonization resistance
of the endogenous microbiota, we investigated whether
selected baseline gut microbiota signatures explained the
variation in the quantified amounts of the probiotic
strains after intervention. However, neither alpha di-
versity measures nor relative abundances of individual
microbial taxa at baseline correlated with the qPCR de-
tected abundances of the administered probiotics mea-
sured at the end of the intervention (data not shown).
Estimation of probiotic proliferation in the infant gut
In order to estimate whether or not the probiotic strains
were proliferating in the gut, we determined the ratios
between fecal excretion and oral intake of the two probiotic
strains based on specific qPCR measurements for infants in
the probiotic group. Intake of each of the probiotic strains,
LGG® and BB-12®, was set as the daily dose of 109 CFU.
The amount of excreted probiotics was calculated as the
qPCR-estimated amount of CFU/g feces multiplied with
the average weight of feces reported to be excreted by
healthy individuals at the given age, which is 80 g/day
[23, 24]. A ratio of fecal excretion to oral input (excre-
tion/input) above 1 was considered to indicate that pro-
biotic growth had occurred in the gut. In this context,
it should be noted that a considerable fraction of probiotics
are expected not to survive gastrointestinal transit, and that
even a ratio just below 1 may thus imply probiotic prolifer-
ation. For the strain BB-12®, a ratio above 1 was found in
86 of the 103 individuals (83.5%), resulting in a median
excretion/intake ratio of 29. While these estimates may be
affected by occurrence of other B. animalis subsp. lactis
strains (which we could not differentiate from the ingested
Table 2 OTUs significantly differentially abundant in probiotics (n = 103) vs. placebo (n = 98)
OTU ID P-value FDR
P-value
Mean abundance (%) NCBI BLAST hit
Probiotics Placebo
OTU_17 1.45E-27 4.97E-25 2.231% 0.018% 100% Bifidobacterium animalis subsp. lactis strain YIT 4121
OTU_50 4.93E-22 8.45E-20 0.086% 0.007% 100% Lactobacillus rhamnosus strain NBRC 3425
OTU_6 0.013 0.870 3.049% 5.504% 100% Eubacterium rectale strain ATCC 33656
OTU_217 0.015 0.870 0.002% <0.001% 99% [Clostridium] lactatifermentans strain G17
OTU_3 0.016 0.870 5.053% 7.642% 100% Bifidobacterium pseudocatenalutum strain B1279
OTU_290 0.016 0.870 0.009% 0.004% 97% Butyricimonas paravirosa strain 214–4
OTU_334 0.018 0.870 0.040% 0.001% 98% Parasutterella excrementihominis strain YIT 11859
OTU_25 0.037 1 0.867% 1.457% 99% Ruminococcus bromii strain ATCC 27255
OTU_60 0.041 1 0.184% 0.117% 100% Barnesiella intestinihominis strain JCM 15079
OTU_230 0.048 1 0.001% <0.001% 94% Ethanoligenens harbinense strain YUAN-3
Table 3 qPCR detection of the probiotic strains in the
probiotics and placebo treatment groups
LGG®
positive
BB-12®
positive
LGG® & BB-12®
positive
Probiotics (n = 103) 94/103 (91.3%) 98/103 (95.1%) 94/103 (91.3%)
Placebo (n = 98) 2/98 (2.0%) 32/98 (31.1%) 1/98 (1.0%)
Total (n = 201) 96/201 (46.8%) 130/201 (64.7%) 95/201 (47.3%)
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BB-12® strain by qPCR), abundance of this subspecies was
on average more than 100-fold lower in the placebo group
(Table 2), suggesting that the other occurring subspecies of
B. animalis subsp. lactis made only an insignificant contri-
bution to the growth estimates. For the LGG® strain, a ratio
above 1 was observed in 46 of the 103 infants (44.7%)
treated with probiotics, resulting in a median excretion/in-
take ratio of 0.9. Noteworthy, all infants with a LGG® ratio
above 1 also had a BB-12® ratio above 1 (Fig. 2a-b). This
shows that both of the probiotic strains were proliferating
in the gut of at least 44.7% of the infants receiving probio-
tics. Comparison of the intestinal bacterial communities of
the probiotics-treated infants with detected growth of either
the BB-12® strain (n = 86) or LGG® strain (n = 46) to the
placebo group (n = 97) did not reveal any differences in
community structure assessed by weighted UniFrac dis-
tances (Fig. 2c-d), when OTU_17 and OTU_50 (repre-
senting the probiotics) were filtered out. Nor did we
find significant differences in alpha diversity measures
(Additional file 1: Figure S4). Finally, no differentially
abundant OTUs were detected in this comparison
(Additional file 1: Table S4 & Table S5), indicating that
the composition of the endogenous microbiota was not
affected despite proliferation of the probiotic strains in
the infant gut.
Discussion
The bacterial strains LGG® and BB-12® represent some
of the most commonly applied commercially available
probiotics, and studies of their putative effects are there-
fore highly relevant. We investigated the impact of a 6
months intervention with daily doses of 109 CFU of
these two probiotic strains on the gut microbiota of in-
fants aged 8–13 months at onset. Community structure
and diversity of the endogenous infant gut microbiota
were not affected despite the fact that the gut microbiota
is characterized by low stability and high responsiveness
in early life [25]. Several comparable reports on pro-
biotic treatments exist. For example, a previous inter-
vention study with the probiotic strains BB-12®, LGG®
and L. acidophilus LA-5® given to pregnant women from
the 36th gestation week until 3-months post-partum
Fig. 2 Sub-analyses of selected samples with active probiotic growth does not reveal impact on gut microbiota community structure. a-b
Estimates of in situ growth of a BB-12® and b LGG® expressed as the ratio of excreted CFUs/day (excretion) to ingested CFUs/day (input) for all
samples within the probiotics group. Means and medians are represented by dashed lines. c-d PCoA plots of weighted UniFrac distances of the
gut microbiota in samples with detected growth of c BB-12® and d LGG® (orange) as compared to placebo (blue) intervention
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addressed gut microbiota development in the offspring
at ages 10d, 3 m, 1y and 2y [21, 26]. While significant
mother-to-infant transmission of LGG® (but not of BB-
12® or LA-5®) is reported, no effects on infant gut
microbiota composition or diversity were found [21, 26],
which is in line with our findings. Similarly, oral adminis-
tration of B. bifidum W23, B. lactis W52 and Lactococcus
lactis W58 during the last 6 weeks of pregnancy and sub-
sequently to offspring at high risk of atopic disease during
the first year of life is reported to have no effect on the en-
dogenous infant gut microbiota composition and diversity,
neither during the intervention nor at a later follow-up
[27]. Also, 8 weeks daily administration of either L.
acidophilus NCFM or B. lactis Bi-07 to infants aged
7–24 months and diagnosed with atopic dermatitis is
reported not to change the composition and diversity
of the main fecal bacterial populations as compared
to a placebo group [28]. While these studies together
strongly suggest that exposure to commonly applied
(non-endogenous) probiotics in early life does not inter-
fere with the natural succession and development of the
infant gut microbiota, they do not consider the fact that
probiotics may not colonize or grow efficiently in all indi-
viduals. In the present study, we thus further conducted
sub-analyses stratifying individuals based on estimates of
probiotic proliferation of the given strain after ingestion,
but still found no support of the hypothesis that ingestion
of the given probiotics alter the endogenous gut micro-
biota. Although our assessment may have underestimated
the number of samples characterized by proliferation of
the ingested probiotics, the selected samples with excre-
tion/intake ratios above 1 represent the most extreme ex-
amples and would be expected to have shown an impact
on gut microbiota composition if this had been affected.
Conclusion
We show that alteration of the early life gut microbial
community was not achieved by oral administration of
LGG® and BB-12® despite proliferation of the ingested
probiotics in the infant intestine. We thus conclude that
modulation of the endogenous microbiota is unlikely to
be the causal mechanism behind putative effects of these
specific probiotic strains on infant health. However, this
does not exclude a direct impact of the strains on the
host intestinal barrier function, gut associated immune
responses and/or systemic metabolic effects, which may
or may not depend on probiotic proliferation.
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of primer specificity for LGG® and BB-12® primers. Figure S4. Gut
microbial alpha diversity measures are not affected by active growth
of probiotics. (PDF 532 kb)
Abbreviations
CFU: Colony forming units; FDR: False Discovery Rate; OTU: Operational
Taxonomic Unit; PCoA: Principal coordinate analysis; qPCR: Quantitative
polymerase chain reaction
Acknowledgements
We thank the participating infants and their families for their contribution to
the study.
Availability of data and materials
Sequencing data are available at NCBI Sequence Read Archive with the Accession
Number SRP100762 under BioProject PRJNA360073.
Funding
The study was funded by Innovation Fund Denmark, grant number 0603-00579B
(ProbiComp) given to KFM and 0603-00487B (Center for Gut, Grain and Greens)
given to TRL. Additionally, funding was provided by University of Copenhagen
and Chr. Hansen A/S.
Authors’ contributions
KFM and AL designed the intervention study. Intervention trial, data and
fecal collection from participants and data analyses on study participant
characteristics were obtained by RPL. MFR performed 16S rRNA amplicon
library preparation and specific qPCR. MFR, MIB & TRL analyzed and
interpreted the data. MFR wrote the paper. All authors read and approved
the final manuscript.
Ethics approval and consent to participate
The study protocol was approved by the Committees on Biomedical Research
Ethics for the Capital Region of Denmark (H-4-2014-032), and the study was
registered at clinicaltrials.org (NCT02180581) at June 30, 2014. The first
participant was enrolled August 22, 2014. All parents signed a consent form.
Consent for publication
Not applicable.
Competing interests
Chr. Hansen A/S provided additional funding for the project, but had no
influence on the interpretation of the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1National Food Institute, Technical University of Denmark, Kemitorvet,
DK-2800 Lyngby, Denmark. 2Department of Nutrition, Exercise and Sports,
University of Copenhagen, Rolighedsvej 26, DK-1958 Frederiksberg C,
Denmark.
Received: 14 June 2017 Accepted: 11 August 2017
References
1. WHO. Health and Nutritional Properties of Probiotics in Food including
Powder Milk with Live Lactic Acid Bacteria. 2001; October:1–34.
2. Collins MD, Gibson GR. Priobiotics, prebiotics, and symbiotics: approaches
for modulating the microbial ecology of the gut. Am J Clin Nut. 1999;
69(suppl):1052S–7S.
3. Hemarajata P, Versalovic J. Effects of probiotics on gut microbiota: mechanisms of
intestinal immunomodulation and neuromodulation. Therap Adv Gastroenterol.
2013;6:39–51.
Laursen et al. BMC Microbiology  (2017) 17:175 Page 8 of 9
4. Putignani L, Del Chierico F, Petrucca A, Vernocchi P, Dallapiccola B. The
human gut microbiota: a dynamic interplay with the host from birth to
senescence settled during childhood. Pediatr Res. 2014;76:2–10.
5. Kristensen NB, Bryrup T, Allin KH, Nielsen T, Hansen TH, Pedersen O.
Alterations in fecal microbiota composition by probiotic supplementation in
healthy adults: a systematic review of randomized controlled trials. Genome
Med. 2016;8:52.
6. Brüssow H. How stable is the human gut microbiota? And why this question
matters. Environ Microbiol. 2016;18:2779–83.
7. Rodríguez JM, Murphy K, Stanton C, Ross RP, Kober OI, Juge N, et al. The
composition of the gut microbiota throughout life, with an emphasis on
early life. Microb Ecol Health Dis. 2015;26:26050.
8. Laursen RP, Larnkjær A, Ritz C, Hauger H, Michaelsen KF, Mølgaard C.
Probiotics and child care absence due to infections: a randomized
controlled trial. Pediatrics. 2017;140:e20170735.
9. Edgar RC. UPARSE: highly accurate OTU sequences from microbial amplicon
reads. Nat Methods. 2013;10:996–8.
10. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello
EK, et al. QIIME allows analysis of high-throughput community sequencing
data. Nat Methods. 2010;7:335–6.
11. Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive Bayesian classifier for rapid
assignment of rRNA sequences into the new bacterial taxonomy. Appl
Environ Microbiol 2007;73:5261–5267. doi:10.1128/AEM.00062-07.
12. DeSantis TZ, Hugenholtz P, Larsen N, Rojas M, Brodie EL, Keller K, et al.
Greengenes, a chimera-checked 16S rRNA gene database and workbench
compatible with ARB. Appl Environ Microbiol. 2006;72:5069–72.
13. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment
search tool. J Mol Biol. 1990;215:403–10.
14. Huson DH, Scornavacca C. Dendroscope 3: an interactive tool for rooted
phylogenetic trees and networks. Syst Biol. 2012;61:1061–7.
15. Brandt K, Alatossava T. Specific identification of certain probiotic
Lactobacillus rhamnosus strains with PCR primers based on phage-related
sequences. Int J Food Microbiol. 2003;84:189–96.
16. Endo A, Aakko J, Salminen S. Evaluation of strain-specific primers for identification
of Lactobacillus rhamnosus GG. FEMS Microbiol Lett. 2012;337:120–5.
17. Briner AE, Lugli GA, Milani C, Duranti S, Turroni F, Gueimonde M, et al.
Occurrence and diversity of CRISPR-Cas systems in the genus bifidobacterium.
PLoS One. 2015;10:e0133661.
18. De Man JC, Rogosa M, Sharpe ME. A medium for the cultivation of
lactobacilli. J Appl Bacteriol. 1960;23:130–5.
19. Benjamini Y, Hochberg Y. Controlling the false discovery rate - a practical
and powerful approach to multiple testing. J R Stat Soc Ser B-Methodological.
1995;57:289–300.
20. Laursen MF, Andersen LBB, Michaelsen KF, Mølgaard C, Trolle E, Bahl MI,
et al. Infant gut microbiota development is driven by transition to family
foods independent of maternal obesity. mSphere. 2016;1:e00069-e00015.
doi:10.1128/mSphere.00069-15.
21. Avershina E, Lundgård K, Sekelja M, Dotterud C, Storrø O, Øien T, et al. Transition
from infant- to adult-like gut microbiota. Environ Microbiol. 2016;18:2226–36.
22. Martin R, Makino H, Cetinyurek Yavuz A, Ben-Amor K, Roelofs M, Ishikawa E, et al.
Early-life events, including mode of delivery and type of feeding, siblings and
gender, shape the developing gut microbiota. PLoS One. 2016;11:e0158498.
23. Burkitt D, Morley D, Walker A. Dietary fibre in under- and overnutrition in
childhood. Arch Dis Child. 1980;55:803–7.
24. Myo-Khin, Thein-Win-Nyunt, Kyaw-Hla S, Thein-Thein-Myint, Bolin TD. A
prospective study on defecation frequency, stool weight, and consistency.
Arch Dis Child. 1994;71:311-3-4.
25. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability
and resilience of the human gut microbiota. Nature. 2012;489:220–30.
26. Dotterud CK, Avershina E, Sekelja M, Simpson MR, Rudi K, Storrø O, et al.
Does maternal perinatal probiotic supplementation alter the intestinal
microbiota of mother and child? A randomized controlled trial. J Pediatr
Gastroenterol Nutr. 2015;61:200–7.
27. Rutten NBMM, Gorissen DMW, Eck A, Niers LEM, Vlieger AM, der Vaart I,
et al. Long term development of gut microbiota composition in atopic
children: impact of probiotics. PLoS One. 2015;10:1–17.
28. Larsen N, Vogensen FK, Gøbe R, Michaelsen KF, Abu Al-Soud W, Sørensen
SJ, et al. Predominant genera of fecal microbiota in children with atopic
dermatitis are not altered by intake of probiotic bacteria Lactobacillus
acidophilus NCFM and Bifidobacterium animalis subsp.lactis Bi-07. FEMS
Microbiol Ecol. 2011;75:482–96.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Laursen et al. BMC Microbiology  (2017) 17:175 Page 9 of 9
